BW234: A nondopamine receptor‐blocking antipsychotic drug without extrapyramidal side effects?
Based on studies in animals and in healthy human volunteers, it was predicted that the carbazole compound BW234U would have antipsychotic effects in patients without producing concomitant extrapyramidal effects. The compound was administered to 22 inpatients with schizophrenia in an open, dose‐ranging pilot study designed to assess antipsychotic effects as well as side effect profile. Clinical changes were observed on the BPRS and global improvement scales over a 4‐week period. No extrapyramidal side effects were noted, and serum prolactin concentrations showed no change in a subsample of nine patients. Two major side effects appeared to be drug‐related: One seizure occurred at 600 mg/day, and elevations of alkaline phosphatase were noted at several doses in six patients. Copyright © 1985 Alan R. Liss, Inc.
Davidson, J; Dren, A; Miller, R; Manberg, P; Kilts, C; Wingfield, M
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)